Policy
The $1.2 trillion budget package will now move to the Senate, which is expected to hold a vote next week.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Pharming categorically denies having had any involvement in the alleged abstraction of proprietary information by Dr Joseph Chiao from his former employer CSL
Frank Reynolds, chief executive officer of PixarBio, made outlandish claims to investors and even compared himself to Apple’s Steve Jobs and Jesus Christ. Those were the claims of a witness made on the witness stand in an ongoing securities fraud trial.
AmerisourceBergen, McKesson and Cardinal Health are in the midst of negotiations for a multi-billion settlement over litigation filed against each of the companies for their role in distributing opioid drugs across the country.
Potential approval would validate the use of Algenex’ CrisBio® technology for the manufacture of recombinant subunit vaccines
Biocair, a global leader in specialist logistics, announced that its Frankfurt office has joined the company’s network of ISO 9001:2015 certified operations.
Alzheimer’s Research UK has responded to an announcement that could see new legislation aimed at providing faster access to medicines.
The Dutch company Xenikos B.V. announced that the U.S. Food and Drug Administration has granted Fast Track designation to T-Guard, Xenikos’ flagship product designed to treat steroid-refractory acute graft-versus-host disease in patients following allogeneic stem cell transplantation.
The patch is a once-per-day treatment that provides sustained concentrations of Secuado (asenapine), an atypical antipsychotic drug used to treat schizophrenia.
Sanofi is pressing the U.S. Food and Drug Administration to keep its patient experience data consistent following a review of approved applications required by the 21st Century Cures Act.
Motif Bio plc announced that the Company has received the official minutes of the Type B meeting with the U.S. Food & Drug Administration which took place on September 19, 2019..